General Psychiatry Archives - MPR

General Psychiatry

Stressed anxious man.

Viloxazine Under Review for ADHD Treatment in Adults

The Food and Drug Administration has accepted for review the supplemental New Drug Application for viloxazine extended-release for the treatment of attention-deficit hyperactivity disorder in adults. The application is supported by data from a multicenter, randomized, double-blind, placebo-controlled phase 3 trial ( Identifier: NCT04016779), which assessed the efficacy and safety of viloxazine in 374 adults…

Invega Hafyera Approved for Twice-Yearly Treatment of Schizophrenia

The Food and Drug Administration has approved Invega Hafyera™ (paliperidone palmitate), an every 6-month injection, for the treatment of schizophrenia in adults. Invega Hafyera is a long-acting atypical antipsychotic that is administered as a gluteal intramuscular injection by a health care professional. Prior to initiating treatment with Invega Hafyera, patients must have been adequately treated…